M Pharmaceutical Appoints Matthew B. Lehman President & CEO Effective September 1, 2015 - Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2015) - M Pharmaceutical (CSE: MQ) (OTCQB: MPHMF) (FWB: T3F2), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, has appointed Matthew B. Lehman as President and CEO, effective September 1, 2015.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "M Pharma" in the search box.

If you cannot view the video above, please visit:

http://www.investmentpitch.com/video/0_g9d09eod/M-Pharmaceutical-CSEMQ-has-appointed-Matthew-B-Lehman-as-President-and-CEO-effective-September-1-2015

Mr. Lehman, with more than 15 years of executive level experience in the development of therapeutics, will be based in Cincinnati, Ohio, where the company expects to establish its U.S. operating presence and focus on the company's most important global market. Mr. Lehman has significant global experience in clinical development, regulatory strategy, intellectual property management, negotiating grants and incentives, and raising capital for R&D stage companies. Most recently, he was the CEO of Prima Biomed Ltd., a public company listed on NASDAQ and the ASX, where he obtained "Fast Track" from the FDA and "Orphan Drug" designation for Prima Biomed's lead product at the time.

Mr. Lehman stated: "I am pleased to join M Pharmaceutical at this crucial time as we plan for the clinical development and global commercialization of our products. Dr. Mintchev and his team have set a great foundation with innovative technologies and strong patent protection. I look forward to working with Dr. Mintchev to expedite development of the Trimeo Weight Loss Capsules, Trimtec Gastric Neurostimulation System, and eMosquito Wearable Blood Monitor."

Dr. Martin Mintchev, the lead inventor of the company's technologies and company co-founder, will transition from his position as CEO to serve as Chief Scientific Officer.

George Tsafalas, a member of the Board of Directors added: "Mr. Lehman brings the company the needed skills and experience to carry our innovative biomedical technologies to the world-wide marketplace and lead the company's development. I would like to thank Dr. Mintchev for his service as the company's founding CEO during our start-up stage and I am pleased that he will continue to serve as the company's Chief Scientific Officer."

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

Upon the announcement of plans to open a fully owned subsidiary in Bulgaria, Dr. Martin Mintchev stated: "Opening a subsidiary in Bulgaria, an European Union member state, demonstrates our commitment to quickly move towards registering Trimeo as a prescription-based medical device for the treatment of obesity in the European Union. We are confident that obtaining CE Mark for Trimeo and starting sales in Europe will strengthen our regulatory position with the U.S. Food and Drug Administration and Health Canada on our quest for subsequently entering the North American market."

On June 24th, New York based SeeThruEquity initiated coverage on M Pharmaceutical, giving the company a target price of $0.79, a premium of 316% to the $0.19 price the day the report was issued.

The shares are currently trading at $0.09, and with 26.3 million shares outstanding, the company is capitalized at $2.4 million. For more information about M-Pharma, please visit the company’s website www.m-pharma.ca, call 604-428-0511 or email info@m-pharma.ca.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:

InvestmentPitch.com

Barry Morgan, CFO

bmorgan@investmentpitch.com